Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

•Updated long-term efficacy and safety data from PRIMA/ENGOT-OV26/GOG-3012 study.•Niraparib first-line maintenance therapy extended progression-free survival (PFS).•Durable PFS benefit observed in overall population and across biomarker subgroups.•The most common grade ≥ 3 adverse events in niraparib patients were haematologic.•No new safety signals were identified.